🔗 Visit the ClinicalTrials.gov page for NCT01614457
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. | Lancet Respir Med | 2015 | 1.74 |
| 2 | On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator. | J Physiol | 2016 | 0.79 |
| 3 | CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. | Front Pharmacol | 2016 | 0.75 |
| 4 | Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency. | Children (Basel) | 2015 | 0.75 |
| 5 | PharmGKB summary: very important pharmacogene information for CFTR. | Pharmacogenet Genomics | 2015 | 0.75 |